ANAB
ANAPTYSBIO, INC
NASDAQ · Healthcare · Biotechnology · US
$46.61
−4.31%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$49.03
From 52W high−33.23%
Volume413631.00
Market cap$1.39B
P/E (TTM)6.9x
P/S (TTM)5.9x
Div yield—
Key dataOct 16, 2026
Open
$49.03
From 52W high
−33.23%
Volume
413631.00
Market cap
$1.39B
ValuationView details →
P/E (Fwd)
5.2x
EV/EBITDA
16.3x
P/E (TTM)
6.9x
RSI (14)
40.0
MomentumView details →
1D Return
−4.31%
YTD Return
+47.12%
SummaryUpdated Jun 1, 2026
AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company founded in 2005 and based in San Diego, California. The company was originally incorporated as Anaptys Biosciences, Inc. before changing its name to AnaptysBio in July 2006. AnaptysBio went public in January 2017 and focuses on developing innovative therapeutic antibody candidates for treating inflammatory diseases and immuno-oncology conditions. The company leverages its proprietary antibody discovery platform to create targeted treatments that modulate immune system responses.
Similar companies
Latest newsMore news →
AnaptysBio, Inc. reported a Q2 loss of $0.11 per share, beating the Zacks Consensus Estimate of a $0.46 loss and improving from a $1.34 loss per share a year earlier.25d agoAnaptysBio, Inc. reported its financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.25d ago